Dr. Rodas Ochoa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
607 Camden St
Ste 108
San Antonio, TX 78215Phone+1 210-253-3426Fax+1 210-237-4807
Education & Training
- Carolinas Medical CenterFellowship, Transplant Hepatology, 2016 - 2017
- St Barnabas HospitalResidency, Internal Medicine, 2009 - 2012
- University of Cuenca Faculty of Medical ScienceClass of 2006
Certifications & Licensure
- FL State Medical License 2012 - 2026
- TX State Medical License 2017 - 2026
- NC State Medical License 2016 - 2018
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Editor Award Annals of Internal Medicine, 2020
Publications & Presentations
PubMed
- High sustained virologic response rates, regardless of race or socioeconomic class, in patients treated with chronic hepatitis C in community practice using a speciali...Saatchi Kuwelker, Eugenia Tsai, Lily Kuo, Jae Kim, Timothy Van Frank
Medicine. 2023-07-28 - NAFLD: A pretransplant and post-transplant conundrum.Fabian V Rodas, Nagasri Shankar
Clinical Liver Disease. 2023-04-01 - 13 citationsReal-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance.Nicole Loo, Bryan Hanysak, Jena Mann, Ruben D. Ramirez, Jae Kim
Medicine. 2019-06-01
Journal Articles
- Real World experience with Direct Acting Antivirals for Hepatitis C: Baseline resistance, efficacy and need for long-term surveillance,Poordad, F. Rodas, F, Medicine 2019
Authored Content
- NAFLD: A pretransplant and post-transplant conundrumMay 2023
Professional Memberships
- Member
- Member
- Member
- American Association for the Study of Liver Disease (AASLD)Member
- European Association for the Study of the Liver (EASL)Member
Industry Relationships
- Principal Investigador, The Texas Liver InstitutePhase 2 NASH Clinical trials2021 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: